Andexanet alfa - Recommendations for clinical use. Multidisciplinary experts' standpoint
Cardiol J
.
2023;30(4):502-505.
doi: 10.5603/CJ.a2023.0043.
Epub 2023 Jul 4.
Authors
Jacek Kubica
1
,
Piotr Adamski
2
,
Robert Gajda
3
,
Mariusz Gąsior
4
,
Marek Gierlotka
5
,
Robert Gil
6
,
Miłosz Jaguszewski
7
,
Aldona Kubica
8
,
Wiktor Kuliczkowski
9
,
Krzysztof Kurek
10
,
Jerzy Robert Ładny
11
,
Piotr Michalski
8
,
Eliano Pio Navarese
2
,
Piotr Niezgoda
2
,
Małgorzata Ostrowska
2
,
Agnieszka Tycińska
12
Affiliations
1
Department of Cardiology and Internal Medicine, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland. jwkubica@gmail.com.
2
Department of Cardiology and Internal Medicine, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland.
3
Gajda-Med Medical Center, Pultusk, Poland.
4
3rd Department of Cardiology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Katowice, Poland.
5
Department of Cardiology, Institute of Medical Sciences, University of Opole, Poland.
6
Mossakowski Medical Research Institute, Polish Academy of Science, Warsaw, Poland.
7
1st Department of Cardiology, Medical University of Gdansk, Poland.
8
Department of Cardiac Rehabilitation and Health Promotion, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland.
9
Institute of Heart Diseases, Wroclaw Medical University, Wroclaw, Poland.
10
Department of Gastroenterology and Internal Medicine, Medical University of Bialystok, Poland.
11
Department of Emergency Medicine, Medical University of Bialystok, Poland.
12
Department of Cardiology, Medical University of Bialystok, Poland.
PMID:
37401419
PMCID:
PMC10508081
DOI:
10.5603/CJ.a2023.0043
No abstract available
MeSH terms
Anticoagulants* / adverse effects
Blood Coagulation*
Factor Xa / pharmacology
Humans
Substances
PRT064445
Anticoagulants
Factor Xa